Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis

NCT01265823 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT01265823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01265823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2010
Completion date
February 29, 2012
Enrollment
150 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis